Health Condition 1: G998- Other specified disorders of nervous system in diseases classified elsewhere
Conditions
Interventions
Intervention1: Tablet Euphorbia Prostrata: Drug Name: Euphorbia prostrata
Dose: 100-200 mg extract Route: Oral Frequency: Twice daily Duration: 7-14 days (acute), 4-12 weeks (chronic) Purpose: Treats
Sponsors
Dr. A.P. Rohith
Eligibility
Inclusion criteria
Inclusion criteria: Adults aged 18 to 65 years with clinically diagnosed primary varicose veins CEAP C2 to C4. Symptomatic patients presenting with pain, swelling, pigmentation, or skin changes. Eligible for treatment with Euphorbia prostrata, Pilex or surgery. Willing to provide informed consent and comply with follow up visits for 24 weeks.
Exclusion criteria
Exclusion criteria: Diagnosis of secondary varicose veins, including cases related to deep vein thrombosis, trauma or congenital venous anomalies. Presence of active venous ulcers CEAP class C5 to C6 or infective dermatitis at the study entry. Known systemic conditions such as hepatic impairment, renal dysfunction, coagulopathies, or uncontrolled diabetes. Pregnancy, lactation or known allergy to study medications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in pain scores (VAS scale) Decrease in bleeding episodes (hemorrhoids) Improvement in heaviness/aching (varicose veins) Objective Clinical Measures Reduction in hemorrhoid size (proctoscopy grading) Improvement in venous refill time (Doppler ultrasound) Decrease in visible varicosity severity (CEAP classification) Timepoint: Baseline visit (Day 1) Day 90 (plus or minus 3 days) Final visit at Day 180 (plus or minus 3 days) - End of study | — |
Secondary
| Measure | Time frame |
|---|---|
| Metabolic & Systemic Parameters BMI, waist circumference Lipid profile (HDL, triglycerides) Glycemic control (HbA1c, fasting glucose) Blood pressure (systolic/diastolic) Liver Safety Profile AST, ALT, ALP, bilirubin levels Patient-Reported Outcomes Quality of life score (disease-specific questionnaire) Number of adverse eventsTimepoint: Baseline visit (Day 1) Day 30 (plus or minus 3 days) Day 60 (plus or minus 3 days) - Telephonic follow-up Day 90 (plus or minus 3 days) Day 135 (plus or minus 3 days) - Telephonic follow-up Final visit at Day 180 (plus or minus 3 days) - End of study | — |
Countries
India
Contacts
Public ContactDr AP Rohith
Srm Institute of Science and Technology
Outcome results
None listed